Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,840 INR | +1.64% |
|
+0.82% | -4.40% |
Jun. 20 | Fosun Pharma Trims Stake in Gland Pharma to 51.83% | MT |
Jun. 18 | Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- With an expected P/E ratio at 33.49 and 28.73 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.40% | 3.63B | B- | ||
+56.89% | 823B | C+ | ||
+39.52% | 627B | B | ||
-6.55% | 353B | C+ | ||
+7.92% | 295B | C+ | ||
+13.74% | 239B | B+ | ||
+13.83% | 220B | B- | ||
-0.49% | 219B | A+ | ||
+7.94% | 167B | C+ | ||
-2.57% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLAND Stock
- Ratings Gland Pharma Limited